Tropical Travel Trouble 009 Humongous HIV Extravaganza
LITFL • Life in the Fast Lane Medical Blog LITFL • Life in the Fast Lane Medical Blog - Emergency medicine and critical care medical education blog aka Tropical Travel Trouble 009 The diagnosis of HIV is no longer fatal and the term AIDS is becoming less frequent. In many countries, people with HIV are living longer than those with diabetes. This post will hopefully teach the basics of a complex disease and demystify some of the potential diseases you need to consider in those who are severely immunosuppressed. While trying to be comprehensive this post can not be exhaustive (as you can imagine any patient with a low ...
Source: Life in the Fast Lane - July 7, 2018 Category: Emergency Medicine Authors: Amanda McConnell Tags: Clinical Cases Tropical Medicine AIDS art cryptococcoma cryptococcus HIV HIV1 HIV2 PEP PrEP TB toxoplasma tuberculoma Source Type: blogs

Memo To The President: The Pharmaceutical Monopoly Adjustment Act Of 2017
Since 1980, Congress has enacted many laws granting pharmaceutical manufacturers monopolies that no other industry enjoys. These extra monopolies were created with the expectation that monopoly profits would spur greater investment in research to find important new drugs. In fact, they have caused US consumers to pay higher prices for medicines for longer periods of time while making the pharmaceutical industry far more profitable than any other industry. I believe the next president and Congress should take several key steps, which I outline below, to roll back these costly, unnecessary monopolies. The Current Landscape C...
Source: Health Affairs Blog - September 13, 2016 Category: Health Management Authors: Alfred Engelberg Tags: Costs and Spending Drugs and Medical Technology Health Policy Lab Bayh-Dole Act Big Pharma Gilead Hatch-Waxman Act johnson & johnson pfizer Source Type: blogs

CMS’ Standardized Plan Option Could Reduce Discrimination
The objective is to make sure shoppers can compare plans on premiums and provider networks, knowing that the rest of the benefit design has largely identical cost-sharing requirements. It has become clear that failing to standardize all benefits could allow insurers to set cost-sharing amounts that discourage enrollment by those with certain chronic diseases. Promoting Standardization Standardized options appear to be an excellent way to ease health plan decisions and reduce or eliminate discriminatory benefit designs. The adoption of such plans should be encouraged to improve choices for consumers. One option would be a r...
Source: Health Affairs Blog - January 6, 2016 Category: Health Management Authors: Douglas Jacobs Tags: Costs and Spending Drugs and Medical Technology Equity and Disparities Featured Payment Policy Quality Adverse Tiering CMS Essential Health Benefits HIV/AIDS Massachusetts New York States Source Type: blogs

Glaxo, Pfizer’s Hiv Treatment Recommended By Eu Regulator
The treatment, approved by the U.S. Food and Drug Administration in August, reduced the HIV virus to undetectable levels in more people than Gilead Sciences Inc. (GILD) s Atripla, the worlds best-selling AIDS drug, in a clinical trial released last year. The medicine, also known as dolutegravir, is an integrase strand transfer inhibitor that interferes with the enzymes necessary for HIV to multiply. Merck & Co. You will find the original content at this website http://www.bloomberg.com/news/2013-11-22/glaxo-pfizer-s-hiv-treatment-recommended-by-eu-regulator.html (Source: aids-write.org)
Source: aids-write.org - November 22, 2013 Category: HIV AIDS Authors: aidswrite Tags: current news hiv news Source Type: blogs

A Fading Vertex Drug Was Also Fastest To Become A Blockbuster
How is this for irony? The same week that Vertex Pharmaceuticals (VRTX) cuts 15 percent of its workforce due to plunging sales of its Incivek treatment for hepatitis C, the drug has been identified as having achieved blockbuster status faster than any other medicine. Incivek was launched in 2011, by the way, and surpassed Celebrex, which is sold by Pfizer (PFE) but was launched in 1999 by Pharmacia. The analysis was conducted by EvaluatePharma which reviewed quarterly US products sales and aggregated the first four full quarters after each drug launch in the region. Only five drugs have ever achieved blockbuster status in ...
Source: Pharmalot - October 31, 2013 Category: Pharma Commentators Authors: esilverman Source Type: blogs

Will Germany Squelch Gilead Hopes For Its Stribild AIDS Drug?
In a move that may make Gilead Sciences execs a wee bit anxious, German regulators have issued a preliminary decision that their once-daily, combination Stribild HIV treatment does not offer a benefit over their older Atripla medication. Stribild, you may recall, contains four different Gilead compounds and is projected to become a multi-billion-dollar seller in a few years. For the moment, there is no reason to suggest the decision means Stribild will not become a success story. The treatment, which won FDA approval last year, has generated more than $190 million in sales in the first six months of this year (see page 20)...
Source: Pharmalot - September 18, 2013 Category: Pharma Commentators Authors: esilverman Source Type: blogs